Biocon Limited (NSE:BIOCON)
India · Delayed Price · Currency is INR | Market Cap | 697.28B +82.7% |
| Revenue (ttm) | 169.27B +14.0% |
| Net Income | 3.86B -24.9% |
| EPS | 2.82 -29.1% |
| Shares Out | 1.62B |
| PE Ratio | 152.78 |
| Forward PE | 52.29 |
| Dividend | 0.50 (0.12%) |
| Ex-Dividend Date | Jul 3, 2026 |
| Volume | 3,777,587 |
| Average Volume | 5,240,238 |
| Open | 433.00 |
| Previous Close | 430.85 |
| Day's Range | 421.75 - 433.20 |
| 52-Week Range | 327.60 - 436.90 |
| Beta | 0.23 |
| RSI | 76.43 |
| Earnings Date | May 7, 2026 |
About Biocon
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, a... [Read more]
Financial Performance
In fiscal year 2025, Biocon's revenue was 152.62 billion, an increase of 3.43% compared to the previous year's 147.56 billion. Earnings were 10.13 billion, a decrease of -0.90%.
Financial StatementsNews
Biocon issues reminder to shareholders for unclaimed dividends before August 2026 deadline
Biocon Limited has issued a reminder to its shareholders to claim unclaimed dividends from the financial year 2018-19 before the deadline of August 20, 2026. The company has highlighted that…
Pharma Stocks Today, May 13: Wockhardt rises 1.97%, Orchid Pharma falls 1.79%, Biocon gains 1.38%
Indian pharmaceutical stocks showed a mixed trend on May 13 2026 during the early morning trading session. The BSE Healthcare index remained nearly flat, rising marginally by 0.04% to 46,087.93.…
Top gainers today: oil India at ₹490.95 up 7.66%, ONGC at ₹294.50 up 4.80%, biocon at ₹402.45 up 3.07%
In a session marked by overall declines in the Indian stock market, with the Sensex down 1.92% at 74,559.24 and the Nifty 50 dropping 1.83% to 23,379.55, several stocks managed…
Pharma sector stocks fall today, May 12: Orchid Pharma falls 3.74%, J.B. Chemicals down 2.67%, Biocon rises 0.79%
Indian pharmaceutical stocks opened lower on May 12 2026. The BSE Healthcare index declined 0.74% to 46,474.08 in the early morning trade. The broader market also remained weak with the…
Pharma Stocks Today, May 11: Torrent Pharma up 3.77%, Lupin falls 4.50%, Biocon rises 3.36%
Pharmaceutical stocks displayed a mixed trend on May 11 2026 during the afternoon trading session. The BSE Healthcare index managed to rise 0.93% to 46,965.52, showing relative strength even as…
Biocon Pharma receives Health Canada approval for micafungin injection
Biocon Pharma Limited, a subsidiary of Biocon Limited, has secured approval from Health Canada for its micafungin for injection, USP, available in 50 mg and 100 mg dosages. This approval…
Biocon Ltd (BOM:532523) Full Year 2026 Earnings Call Highlights: Strong Biosimilars Growth and ...
Biocon Ltd (BOM:532523) Full Year 2026 Earnings Call Highlights: Strong Biosimilars Growth and Strategic Deleveraging
Full Year 2026 Biocon Ltd Earnings Call Transcript
Full Year 2026 Biocon Ltd Earnings Call Transcript
Biocon Earnings Call Transcript: Q4 2026
FY 2026 saw strong biosimilars-led growth, improved margins, and successful integration of business units. The company completed its major investment phase, shifted focus to execution and de-leveraging, and expects new product launches to drive further growth and profitability in FY 2027.
Biocon Quarterly report: Q4 2026
Biocon has published its Q4 2026 quarterly earnings report on May 7, 2026.
Biocon Slides: Q4 2026
Biocon has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 7, 2026.
Biocon Earnings Call Transcript: Q4 2026
Q4 FY 2026 saw strong revenue and margin growth, driven by biosimilars and successful business integration. Focus shifts to execution, margin expansion, and de-leveraging, with no major CapEx planned and new product launches expected to drive growth in FY 2027.
Biocon Quarterly report: Q4 2026
Biocon has published its Q4 2026 quarterly earnings report on May 7, 2026.
Biocon Slides: Q4 2026
Biocon has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 7, 2026.
Top Stocks For Trade Today, May 8: Thermax, Dabur India, Biocon, MGL, ONGC, Oil India and more
Indian stock market investors are expected to track a mix of Q4 earnings, major order wins, block deals, and developments linked to crude oil prices on May 8. Here are…
Biocon reports Rs 17,270 crore total income for FY26 with 14% growth
Biocon Limited, an innovation-led global biopharmaceuticals company, announced its consolidated financial results for the fiscal fourth quarter and the financial year ended March 31, 2026. The company...
Pharma sector stocks today, May 7: Wockhardt falls 4%, Panacea Biotec jumps 2.16%, Biocon up 1%
Pharma sector performance remained largely stable in early trading on May 7, 2026. The NIFTY PHARMA Index stood at 24,108.9, showing no change (down 0.0%). The broader S&P BSE HEALTHCARE…
Mazumdar-Shaw picks niece Claire as Biocon successor
India Business News: Kiran Mazumdar-Shaw, founder and chairperson of Biocon, has found her successor within the family. She outlined a gradual succession plan, naming her .
Who Is Claire Mazumdar? Meet Kiran Mazumdar-Shaw's Chosen Successor At Biocon
Claire Mazumdar, 37, is a biotech specialist and the founding CEO of Bicara Therapeutics, a clinical-stage oncology firm incubated by Biocon.
Who is Claire Mazumdar? Kiran Mazumdar-Shaw's Chosen Successor At Biocon
Claire Mazumdar, 37, is a biotech specialist and the founding CEO of Bicara Therapeutics, a clinical-stage oncology firm incubated by Biocon.
Kiran Mazumdar-Shaw picks niece Claire Mazumdar as successor at Biocon: Report
Claire Mazumdar, 37 years of age, currently heads Bicara Therapeutics as its founder and CEO. The firm, which was incubated by Biocon and later listed on NASDAQ, went public in 2024 and now has a mark...
Pharma sector stocks today, April 30: Biocon falls 1.01%, Torrent Pharma down 0.95%, Zydus Lifesciences drops 0.85%
Indian pharmaceutical stocks opened the last trading session of April 2026 on a broadly weak note, with the majority of pharma scrips trading in the red in early trade. The…
Biocon receives five observations from U.S. FDA after pre-license inspection
The U.S. Food and Drug Administration (FDA) has concluded a Pre-License Inspection (PLI) at Biocon's biosimilars site located at Biocon Park in Bengaluru, India. The inspection, which took place from…
Biocon reports Rs 200 crore commercial paper issuance for March quarter
Biocon Limited has issued a quarterly certificate confirming the utilisation of proceeds from its commercial paper (CP) issuance for the quarter ending 31 March 2026. The total issuance of CPs…
Gadkari promised to repair Hosur Rd by April-end: Shaw
Bengaluru: Biocon chairperson and entrepreneur Kiran Mazumdar-Shaw Thursday said Union minister for road transport and highways Nitin Gadkari had assu.